# Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients

> **NCT05002140** · PHASE1 · COMPLETED · sponsor: **XRad Therapeutics Inc** · enrollment: 12 (actual)

## Conditions studied

- Metastasis
- Locally Advanced Solid Tumor
- Recurrent Cancer

## Interventions

- **DRUG:** XRD-0394
- **RADIATION:** Palliative radiotherapy

## Key facts

- **NCT ID:** NCT05002140
- **Lead sponsor:** XRad Therapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-24
- **Primary completion:** 2023-07-21
- **Final completion:** 2023-07-21
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2024-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05002140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05002140, "Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05002140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*